<DOC>
	<DOCNO>NCT00463346</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy acamprosate patient alcohol dependence comorbid schizophrenia spectrum disorder . - 1 : Relative placebo , acamprosate significantly increase cumulative day abstinence recently detoxify alcohol dependent schizophrenia patient measure Timeline Follow-Back ( TLFB ) method . - 2 : Acamprosate significant effect psychotic symptom schizophrenia patient alcohol dependence measure Positive Negative Syndrome Scale ( PANSS ) .</brief_summary>
	<brief_title>Treatment With Acamprosate Patients With Schizophrenia Comorbid Alcoholism</brief_title>
	<detailed_description>Alcohol use disorder ( AUD ) common comorbid condition patient schizophrenia , cause negative impact expression course schizophrenia . Improvements report attain abstinence alcohol , suggest effective treatment AUD lead clinically meaningful result . Acamprosate recently approve treatment alcoholism , may advantageous treatment since metabolize liver , use safely psychotropic medication . Therefore , acamprosate would promise treatment schizophrenia patient . However , report current literature evaluate efficacy medication available treatment alcoholism patient schizophrenia , efficacy safety acamprosate never study vulnerable group patient . Research Design : This 12-week , randomize , double blind , placebo control trial acamprosate ( 666 mg tid ) addition neuroleptic 30 recently abstinent ( &gt; 5 day ) schizophrenia patient comorbid alcohol dependence . Methods : The study conduct West Haven , CT VA support Forest Laboratories . Patients 21 65 , diagnosis schizophrenia spectrum disorder , ( stable psychotropic treatment &gt; 2 week ) current alcohol dependence ( &gt; 1 recent episode heavy drinking ) include . Patients willing undergo detoxification self discontinuation &gt; 2weeks prior randomization . Main outcome variable include TLFB method document degree daily alcohol consumption , PANSS , assess psychotic symptom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Inclusion Criteria 1 . Men woman 21 65 year age . 2 . Patients diagnosis schizophrenia , schizoaffective disorder , psychotic disorder NOS determine Structured Clinical Interview DSMIV Axis I Disorders ( SCID ) [ 22 ] . 3 . Patients stable treatment psychotropic medication &gt; 2 week prior randomization . 4 . Patients current alcohol dependence , least one recent episode heavy drinking ( defined 5 drink per drinking episode ) past 21 day , willing undergo detoxification self discontinuation ( least 5 day ) . 5 . Patients , able comprehend satisfactorily comply protocol requirement . 6 . Patients capacity provide inform consent prior enter study procedure . Exclusion Criteria 1 . Patients dementia , amnestic cognitive disorder . 2 . Patients unstable medical disease medical condition , Investigator 's opinion , would expose increase risk significant adverse event interfere assessment safety efficacy course trial 3 . Patients history opioid dependence within past month . 4 . Patients history intolerance hypersensitivity acamprosate . 5 . Patients currently take disulfiram naltrexone . 6 . Patients base history mental status examination significant risk suicide . 7 . Patients homicidal violent Investigator 's opinion significant imminent risk hurt others . 8 . Women pregnant nursing , woman childbearing potential sexually active use adequate contraception , judge unreliable use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Treatment</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>